Lawrence Ross
Nephrology · Bronx, NYNPI 1962466201
Payments from drug & device makers
Across 92 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$270
- Novo Nordisk$192
- Amgen$159
- AstraZeneca$139
- Boehringer Ingelheim$134
- Hikma Pharmaceuticals USA$117
- plus $606 from 13 others
What the payments were for
- Food & beverage$1,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $270 |
| Novo Nordisk | 12 | $192 |
| Amgen(2 entities) | 9 | $159 |
| AstraZeneca | 8 | $139 |
| Boehringer Ingelheim | 7 | $134 |
| Hikma Pharmaceuticals USA | 7 | $117 |
| Lilly USA, LLC | 7 | $110 |
| Bayer | 3 | $83 |
| Akebia Therapeutics Inc | 5 | $83 |
| Pfizer | 4 | $66 |
| GSK | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| AbbVie | 2 | $38 |
| Evoke Pharma, Inc. | 2 | $38 |
| Vifor Pharma, Inc. | 2 | $28 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Novartis | 1 | $14 |
How this compares
$1,617 in reported general payments places this provider in the 60th percentile of 935 nephrology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 20 | $22,171 |
| EliquisApixaban | 15 | $12,987 |
| JanuviaSitagliptin Phosphate | 13 | $7,683 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,200 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,345 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $1,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,037 |
| Atorvastatin Calcium | 95 | $1,021 |
| Omeprazole | 42 | $445 |
| Levothyroxine Sodium | 36 | $368 |
| Rosuvastatin Calcium | 21 | $367 |
| Metformin Hcl | 40 | $348 |
| Amlodipine Besylate | 47 | $346 |
| Tamsulosin Hcl | 29 | $292 |
| Sertraline Hcl | 15 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $192 | $22,17120 claims |
| PfizerEliquis | $66 | $12,98715 claims |
| MerckJanuvia | $270 | $7,68313 claims |
| GSKBreo Ellipta | $52 | $4,20011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 935 nephrology providers in New York.
Other nephrology in Bronx
- Robert LynnBronx$2M
- Bruce SpinowitzBronx$837K
- Matthew AbramowitzBronx$749K
- Enver AkalinBronx$312K
- Chang XuBronx$257K
- Joel NeugartenBronx$256K
- Chaim CharytanBronx$204K
- Gill FreiBronx$188K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.